ifosfamide

P2/3, N=437, Active, not recruiting, Children's Oncology Group | Recruiting --> Active, not recruiting | Initiation date: Jul 2026 --> Nov 2025

P1, N=43, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed | Trial completion date: Dec 2026 --> Oct 2025 | Trial primary completion date: Dec 2026 --> Oct 2025

P2, N=15, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University

The patient was started on multimodality VAC-IE (vincristine, doxorubicin, and cyclophosphamide alternating with ifosfamide and etoposide) chemotherapy. Comprehensive imaging, histopathology, IHC, and molecular analysis remain indispensable for diagnosis. Early recognition and a multidisciplinary treatment approach are essential to improving outcomes in this aggressive disease.

P2, N=37, Recruiting, David Bond, MD | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026

Both lung lesions were surgically resected, followed by adjuvant chemotherapy with ifosfamide and doxorubicin. This case emphasizes that even histologically benign-appearing prostatic SFTs can demonstrate malignant potential. It also underscores the necessity of long-term surveillance and contributes to the literature by reporting the first known case of a metastatic SFT originating from the prostate gland.

P3, N=550, Completed, Italian Sarcoma Group | Active, not recruiting --> Completed

P1/2, N=45, Completed, University of Washington | Active, not recruiting --> Completed

The trial comprised two parts: a 3 + 3 dose-escalation CDP1 monotherapy study to determine the dose for the combination study, in which 12 patients with advanced solid tumors received CDP1 alone, and a CDP1-chemotherapy combination study, in which 20 patients with recurrent or metastatic penile cancer received CDP1 combined with the paclitaxel-ifosfamide-cisplatin regimen (TIP). Among penile cancer patients receiving the combination therapy, the objective response rate was 74%, tumor downstaging enabled surgery in seven patients (35%), and the median progression-free survival was 6.9 months. In conclusion, the combination of an anti-EGFR monoclonal antibody and chemotherapy was well tolerated and showed potential efficacy in penile cancer, supporting further investigation.

P2/3, N=437, Recruiting, Children's Oncology Group | Not yet recruiting --> Recruiting | Initiation date: Dec 2025 --> Jul 2026

In May 2025, the patient initiated intravenous chemotherapy consisting of pegylated liposomal doxorubicin and ifosfamide. This case highlights the importance of early integration of histopathological and molecular evaluation for progressive thyroid lesions. The co-occurrence of NF1 and BCORL1 mutations, along with TP53 and TERT promoter alterations, may underlie the tumor's aggressive biological behavior and supports the incorporation of molecular subtyping strategies in TLS management.

AI therapy is useful for advanced or recurrent MPTs. The observed clinical benefit of pazopanib in a patient with FGFR1 N546K-mutated MPT suggests that FGFR1 kinase domain mutations may be a relevant factor in responsiveness of FGFR1-targeted therapy. Further data accumulation is warranted.